Re5 depression treatment (T-PEMF) was investigated in 5 studies (1 RCT and 4 cohorts) with a total of 159 patients - a smaller body of evidence compared to ECT or rTMS. The studies showed:

• remission rates between 30-70%, that ECT non-responders can benefit from Re5 depression treatment, and that there is a possible effect on quality of life (WHO-5 included in 2 of the studies)
• Re5 depression treatment did not result in serious complications and was generally well tolerated (few, transient and mild side effects) and that T-PEMF can be used as an add-on with all groups of psychotropic drugs
• Re5 depression treatment is user-friendly and flexible (can be used as home treatment after initial instruction)

Thus, the results of the treatment are strong. The majority of the results are generated from patients with difficult-to-treat (treatment-resistant) depression and yet significant response is seen if all 8 weeks are completed.

So far, over 60 percent of those treated have experienced either complete freedom from symptoms or a significant improvement in their condition. Of particular note, the reduction in depression assessed by the Hamilton-D6 was significant and over 50% achieved remission on this parameter, which encompasses the core symptoms of the disease.

Among those who achieved complete freedom from symptoms, over half remained symptom-free two years after treatment. For those who experienced a relapse two years after treatment, resuming treatment proved to be highly effective.

Among those who experienced side effects, these were generally mild and transient, including symptoms such as mild nausea or headache, typically occurring at the beginning of the treatment course. Data from the clinical studies also showed that side effects related to any concomitant antidepressant medication were significantly reduced by the treatment.

Furthermore, Re5 depression treatment is convenient and works well in the clinic, and the home treatment option increases flexibility for clinicians and patients.

You can see an overview of the research with Re5 depression treatment.